Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Researchers take first steps in developing 'paintable' chemotherapy for melanoma

Skin acts as the first line of defense against pathogens and other harmful material from outside the body. Yet this barrier also excludes some beneficial drugs that could treat skin diseases.

26 Sep 2018

Researchers discover novel targeting agents to prevent cancer metastasis

Recently, a research team led by Maurizio Pellecchia at the University of California, Riverside, discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

26 Sep 2018

FDA approves new 5 mm diameter drug-eluting stent from Cook Medical

Cook Medical announced that a new 5 mm diameter version of Zilver® PTX® was approved by the FDA. It is the first 5 mm drug-eluting stent in the U.S. with lengths available up to 140 mm that is indicated to treat vessels as small as 4mm in diameter.

25 Sep 2018

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

BeiGene, Ltd., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, and SpringWorks Therapeutics, a clinical-stage rare disease and oncology company focused on sourcing and developing innovative treatments for underserved patient populations, announced today that the companies have entered into a global clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining BeiGene's investigational RAF dimer inhibitor, lifirafenib and SpringWorks Therapeutics' investigational MEK inhibitor, PD-0325901, in patients with advanced solid tumors.

6 Sep 2018

Researchers develop better options to treat peripheral artery disease

Cristina Sabliov, LSU Biological and Agricultural Engineering professor, and Tammy Dugas, professor in the LSU School of Veterinary Medicine's Department of Comparative Biomedical Sciences, have joined forces to fight peripheral artery disease, or PAD, an ailment affecting 8 million Americans.

29 Aug 2018

Drug coated balloons are as good as stent implants for treating small blocked arteries

A removable balloon is as good as a permanent stent implant for opening small blocked arteries, according to late breaking results from the BASKET-SMALL 2 trial presented in a Hot Line Session today at ESC Congress 2018 and simultaneously published in The Lancet.

28 Aug 2018

Researchers launch clinical trial to assess new drug combination against metastatic breast cancers

Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.

28 Aug 2018

European Commission approves Pfizer’s first oncology biosimilar

Pfizer Inc. today announced the European Commission has approved TRAZIMERA, a biosimilar to Herceptin (trastuzumab), for the treatment of human epidermal growth factor overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

31 Jul 2018

Atlantic Health System starts enrolling patients in four pancreatic cancer clinical trials

Atlantic Health System is now enrolling patients in four pancreatic cancer clinical trials. Angela Alistar, MD, a nationally known expert on pancreatic cancer, is serving as national Principal Investigator on the first trial and as local PI on three other trials.

30 Jun 2018

New findings could help fine-tune treatment for cancer patients

Cancer therapies that cut off blood supply to a tumor could be more effective in combination with existing chemotherapeutic drugs - according to new research from the University of East Anglia.

25 May 2018

Study reveals new protective mechanism for tumor cells in breast cancer

Greater knowledge of the mechanisms that contribute to the survival of tumor cells is key to vanquishing them.

25 May 2018

Researchers uncover novel approach for treating neuropathic pain

Neuropathic pain is the chronic, pathological pain that continues even when the cause of pain is removed. Causes include damage to nerve cells and medicines used to treat cancer.

4 May 2018

Treating metastatic breast cancer with immunotherapy

Breast cancer, in the stage with distant metastases, is an incurable disease with a 5 years survival rate of about 5-10%. Immunotherapy has recently improved survival in metastatic breast cancer patients with breast cancer harboring the expression of HER 2 receptor.

19 Mar 2018

UC Riverside researchers discover way to halt cancer metastasis

A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

23 Feb 2018

Study finds specific protein that plays role in breast cancer metastasis

Researchers from the University of Liverpool have found an explanation for how breast cancer spreads to the lungs, which could potentially hold the key to preventing the progression of the disease.

25 Jan 2018

HKBU experts develop new generation of smart anti-cancer drug molecules

The toxic nature of chemotherapy poses a great challenge to clinical treatment of cancer. A team of scholars from the School of Chinese Medicine of Hong Kong Baptist University devoted their efforts to the development of a new generation of smart anti-cancer drug molecules.

15 Dec 2017

New first line combination therapy shows promising results in patients with advanced NSCLC

A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of phase III IMpower150 trial presented at the ESMO Immuno Oncology Congress 2017.

7 Dec 2017

Researchers find potential approach to prevent peripheral neuropathy

In discovering how certain chemotherapy drugs cause the nerve damage known as peripheral neuropathy, researchers at Dana-Farber Cancer Institute have found a potential approach to preventing this common and troublesome side effect of cancer treatment.

11 Oct 2017

FDA approved drug found to have anti-cancer activity against previously unknown targets

Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test new drugs quicker and more efficiently.

10 Oct 2017

Drug approved to treat parasitic infections also exerts anti-tumor effect on EOC cells

Osaka Researchers, in partnership with other Japanese and U.S. scientists, report a new gene target, KPNB1, for treatment against epithelial ovarian cancer (EOC).

28 Sep 2017